SCHEMBL1433090

SCHEMBL1433090

CCN(C)c1ccc(Br)cn1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 5/20 0.69
AOC3 Q16853 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
HCAR3 P49019 1/20 0.40
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.40
TRPV1 Q8NER1 1/20 0.37
RAB9A P51151 3/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5237488 0.86 GBA1 (0.60) GBA1AOC3HCAR3ALDH1A1NPC1
SCHEMBL1432671 0.85 GBA1 (0.59) GBA1AOC3HCAR3ALDH1A1NPC1
SCHEMBL31217157 0.82 GBA1 (0.56) GBA1AOC3HCAR3NPC1SMN1; SMN2
SCHEMBL17316578 0.82 GBA1 (1.00) GBA1AOC3HCAR3ALDH1A1NPC1
SCHEMBL31217223 0.80 GBA1 (0.54) GBA1AOC3HCAR3ALDH1A1NPC1
SCHEMBL5255404 0.79 GBA1 (0.53) GBA1HCAR3ALDH1A1NPC1SMN1; SMN2
SCHEMBL31217283 0.79 GBA1 (0.53) GBA1HCAR3ALDH1A1NPC1SMN1; SMN2
SCHEMBL304232 0.79 GBA1 (0.61) GBA1ALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL2256335 0.78 GBA1 (0.51) GBA1HCAR3
SCHEMBL17316412 0.78 GBA1 (0.51) GBA1HCAR3ALDH1A1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368104-A1 Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same DONG WHA PHARM. CO., LTD. (KR) 2024-11-07 US disclosed
EP-3227287-B1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE Bayer Pharma AG (DE) 2019-08-07 EP disclosed
US-10292970-B2 Heteroaryl-substituted imidazo[1,2-A]pyridines and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-05-21 US disclosed
US-20170304278-A1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-26 US disclosed
EP-3227287-A1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2017-10-11 EP disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 US disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 US disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 US disclosed
WO-2016087343-A1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-09 WO disclosed
EP-2886534-A1 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-Tech Ueno, Ltd. (JP) 2015-06-24 EP disclosed
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R TECH UENO LTD (JP) 2015-06-18 US disclosed
US-8999989-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2015-04-07 US disclosed
US-8999989-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2015-04-07 US disclosed
US-8999989-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2015-04-07 US disclosed
EP-2300430-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-Tech Ueno, Ltd. (JP) 2011-03-30 EP disclosed
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2011-03-10 US disclosed
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2011-03-10 US disclosed
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2011-03-10 US disclosed
WO-2009145360-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2009-12-03 WO disclosed
WO-2009145360-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R-TECH UENO, LTD. (JP) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368104-A1 Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same IL5, ACE2, IL15 GBA1 3402/4885AOC3 3006/4885PIK3CD 3619/4885
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR VAPB, VAPA, BET1 GBA1 1498/4885AOC3 438/4885PIK3CD 4490/4885
US-20110059957-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR VAPB, VAPA, BET1 GBA1 1498/4885AOC3 438/4885PIK3CD 4490/4885
US-20170304278-A1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE TNNI3, CYP11B2, PPIP5K2 GBA1 2431/4885AOC3 1246/4885PIK3CD 1177/4885
US-10292970-B2 Heteroaryl-substituted imidazo[1,2-A]pyridines and their use TNNI3, CYP11B2, PPIP5K2 GBA1 2431/4885AOC3 1246/4885PIK3CD 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.